Opinion|Videos|July 8, 2024
Outcomes from NATALEE and MonarchE
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
Advertisement
Video content above is prompted by the following:
- (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
- How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
- (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
- Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
Advertisement
Related to this article
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
The approval is based on findings from the phase 3 SCOUT-HCM trial.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
4
FDA Expands Mavacamten Label to Include Children With oHCM
5